Assessing Long-Term Liver Safety of Statins and PCSK9 Inhibitors Using Human Genetics.
作者信息
Vujkovic Marijana
机构信息
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
出版信息
Cell Mol Gastroenterol Hepatol. 2024;17(1):173-174. doi: 10.1016/j.jcmgh.2023.10.008. Epub 2023 Nov 6.
Abstract
摘要
相似文献
1
Assessing Long-Term Liver Safety of Statins and PCSK9 Inhibitors Using Human Genetics.利用人类遗传学评估他汀类药物和PCSK9抑制剂的长期肝脏安全性。
Cell Mol Gastroenterol Hepatol. 2024;17(1):173-174. doi: 10.1016/j.jcmgh.2023.10.008. Epub 2023 Nov 6.
2
Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study.评估中国青少年调脂药物的安全性：药物靶点孟德尔随机化研究。
BMC Med. 2023 Oct 31;21(1):410. doi: 10.1186/s12916-023-03115-y.
3
Evaluating the Cardiovascular Impact of Genetically Proxied PCSK9 and HMGCR Inhibition in East Asian and European Populations: A Drug-Target Mendelian Randomization Study.评估东亚和欧洲人群中基因代理的前蛋白转化酶枯草溶菌素9型（PCSK9）和3-羟基-3-甲基戊二酰辅酶A还原酶（HMGCR）抑制对心血管的影响：一项药物靶点孟德尔随机化研究。
Circ Genom Precis Med. 2024 Feb;17(1):e004224. doi: 10.1161/CIRCGEN.122.004224. Epub 2024 Jan 23.
4
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.前蛋白转化酶枯草溶菌素9（PCSK9）与3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制作用及认知功能的孟德尔随机化研究
J Am Coll Cardiol. 2022 Aug 16;80(7):653-662. doi: 10.1016/j.jacc.2022.05.041.
5
First-in-human gene editing for lipid lowering: the initial results.首次人体基因编辑降血脂：初步结果
Cardiovasc Res. 2024 Mar 30;120(4):e5-e8. doi: 10.1093/cvr/cvae037.
6
Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis.他汀类药物或前蛋白转化酶枯草溶菌素 9 型抗体降低胆固醇对白内障的影响：一项荟萃分析。
J Clin Lipidol. 2018 May-Jun;12(3):728-733. doi: 10.1016/j.jacl.2018.02.002. Epub 2018 Feb 8.
7
Safety of PCSK9 inhibitors.PCSK9 抑制剂的安全性。
Biomed Pharmacother. 2022 Dec;156:113957. doi: 10.1016/j.biopha.2022.113957. Epub 2022 Nov 8.
8
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.基于贝叶斯网络的 PCSK9 抑制剂、他汀类药物和依折麦布联合或不联合他汀类药物用于心血管结局的荟萃分析。
Eur J Prev Cardiol. 2018 May;25(8):844-853. doi: 10.1177/2047487318766612. Epub 2018 Mar 23.
9
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.PCSK9（前蛋白转化酶枯草溶菌素 9）抑制剂潜在长期靶标副作用的遗传评估。
Circ Genom Precis Med. 2019 Jan;12(1):e002196. doi: 10.1161/CIRCGEN.118.002196.
10
PCSK9 Pleiotropism: In the Same Vein as Statins.前蛋白转化酶枯草溶菌素9的多效性：与他汀类药物同理
Circ Res. 2022 Nov 11;131(11):890-892. doi: 10.1161/CIRCRESAHA.122.322035. Epub 2022 Nov 10.
本文引用的文献
1
Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.评估 PCSK9 和 HMGCR 抑制对肝功能的影响：四种血统的药物-靶点孟德尔随机分析。
Cell Mol Gastroenterol Hepatol. 2024;17(1):29-40. doi: 10.1016/j.jcmgh.2023.09.001. Epub 2023 Sep 11.
2
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.在已确诊动脉粥样硬化性心血管疾病患者中使用长效依洛尤单抗的研究
Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29.
3
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.用于降低 LDL 胆固醇和载脂蛋白 B 的新出现的治疗方法：JACC 焦点研讨会 1/4。
J Am Coll Cardiol. 2021 Mar 30;77(12):1564-1575. doi: 10.1016/j.jacc.2020.11.079.
4
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.PCSK9 功能丧失对大型多民族队列的冠状动脉外动脉粥样硬化性心血管疾病具有保护作用。
PLoS One. 2020 Nov 9;15(11):e0239752. doi: 10.1371/journal.pone.0239752. eCollection 2020.
5
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.他汀类药物的安全性及相关不良反应：美国心脏协会的科学声明。
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073.
6
Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea.胆红素作为心血管完整性的多效保护剂：不仅仅是一个激进的想法。
Am J Physiol Heart Circ Physiol. 2018 Sep 1;315(3):H429-H447. doi: 10.1152/ajpheart.00417.2017. Epub 2018 Mar 30.
7
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
8
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.载脂蛋白 B 代谢关键基因 PCSK9 和 HMGCR 变异与心血管疾病和糖尿病风险
N Engl J Med. 2016 Dec 1;375(22):2144-2153. doi: 10.1056/NEJMoa1604304.
9
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.《2016年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2016 Jan 26;133(4):e38-360. doi: 10.1161/CIR.0000000000000350. Epub 2015 Dec 16.
10
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.更强化降低 LDL 胆固醇的疗效和安全性：来自 26 项随机试验中 170000 名参与者数据的荟萃分析。
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
Zotero 插件